The development of cell and gene therapies (CGT) hold great promise for treating previously untreatable conditions, but navigating the approval process presents a significant challenge. This article outlines the complex steps involved, from initial discovery to FDA review, and emphasizes the importance of strategic partnerships to ensure these innovative therapies reach patients safely and effectively.